首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Recent advances in design of electrochemical affinity biosensors for low level detection of cancer protein biomarkers using nanomaterial-assisted signal enhancement strategies
【24h】

Recent advances in design of electrochemical affinity biosensors for low level detection of cancer protein biomarkers using nanomaterial-assisted signal enhancement strategies

机译:电化学亲和力生物传感器设计的最新进展,用于使用纳米材料辅助信号增强策略进行癌症蛋白生物标志物的低水平检测

获取原文
获取原文并翻译 | 示例
           

摘要

Highlights ? Control and early diagnosis of cancer via low level detection of tumor markers in biological samples. ? Design of electrochemical affinity biosensors for low level detection of cancer protein biomarkers. ? Application of nanomaterial-assisted signal enhancement strategy. ? Use of antibodies, aptamers, lectins and peptides as biorecognition probes. ? Cancer biomarkers: AFP, APT, CA125, CA15-3, CA19-9, CEA, HE4, HER2, ILs, MUC 1, PDGF, PSA, SCC-Ag, TNF-α, VEGF165. Abstract The main advances in control and early diagnosis of cancer is greatly aided by low level detection of tumor markers in biological samples. Extensive efforts have been devoted to developing some ultrasensitive electrochemical biosensors for detection of cancer markers with high selectivity. These efforts include the development of the bioreceptors with high specificity and affinity, synthesis of novel signal amplifiers based on nanomaterials and the exploration of appropriate design strategies. Electrochemical measurement protocols are suitable for mass fabrication of miniaturized devices. They have a major role in the move towards rapid and simplified testing for point-of-care usage. This review discusses the remarkable advances of the last 6 years in the electrochemical affinity biosensors for determination of protein and glycoprotein tumor markers, with a particular focus on antibodies and aptamers as biorecognition probes.
机译:强调 ?通过低水平检测生物样品肿瘤标志物的控制及早期诊断。还是癌症蛋白生物标志物低水平检测电化学亲和力生物传感器的设计。还是纳米材料辅助信号增强策略的应用。还是使用抗体,适体,凝集素和肽作为生物释认探针。还是癌症生物标志物:AFP,APT,CA125,CA15-3,CA19-9,CEA,HE4,HER2,ILS,MUC1,PDGF,PSA,SCC-AG,TNF-α,VEGF165。摘要对生物样品中肿瘤标志物的低水平检测,癌症控制和早期诊断的主要进展是极大的辅助。已经致力于开发一些超细电化学生物传感器,以检测具有高选择性的癌症标记的广泛努力。这些努力包括具有高特异性和亲和力的生物团体的发展,基于纳米材料的新型信号放大器的合成以及适当设计策略的探索。电化学测量方案适用于小型化装置的大规模制造。它们在旨在对护理点使用点的快速和简化测试方面具有重要作用。本综述讨论了用于测定蛋白质和糖蛋白肿瘤标志物的电化学亲和力生物传感器在过去6年中的显着进展,特别关注抗体和适体作为生物释认探针的抗体和适体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号